From this viewpoint, The specific blocking the TLR9 pathway in vulnerable critically ill COVID-19 patients, might even be a more targeted approach with potentially less side effects than investigational broad-spectrum (hydroxy)chloroquine. The gene discussed is TLR9; the disease is COVID-19.